Garg, M., Kanojia, D., Mayakonda, A., Ganesan, T. S., Sadhanandhan, B., Suresh, S., S., S., Nagare, R. P., Said, J. W., Doan, N. B., Ding, L., Baloglu, E., Shacham, S., Kauffman, M., Koeffler, H. P. (2025). Retraction Note: Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin. Scientific Reports. https://doi.org/10.1038/s41598-025-31415-1